The subsidy of pharmaceuticals in Australia: processes and challenges.
The increasing costs of health care, including new technologies and pharmaceuticals, pose challenges for all countries both in the developed and the developing world. It is essential that the increased expenditure on pharmaceuticals represents value for money and is seen as an investment in health care rather than simply the purchase of the latest released agent. The system in Australia uses a cost-effectiveness approach to guide the decisions as to whether a new drug can be recommended for subsidy. The need for a greater understanding and transparency of the processes is essential in order for a well-informed public debate to occur about the challenges to the system and its sustainability. The relevant issues are discussed in this article to assist that debate.
Sansom
Lloyd
L
School of Pharmacy and Medical Sciences, University of South Australia, Adelaide 5000, South Australia. lloyd.sansom@unisa.edu.au
D026683:Advisory Committees / Q000331:legislation & jurisprudence / Q000458:organization & administration*; D001315:Australia; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D003659:Decision Making, Organizational; D019049:Developed Countries / Q000191:economics; D017277:Drug Approval / Q000331:legislation & jurisprudence / Q000458:organization & administration*; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence* / Q000639:trends; D011307:Drug Prescriptions / Q000191:economics; D005380:Financing, Government / Q000331:legislation & jurisprudence*; D005569:Formularies as Topic; D006297:Health Services Accessibility / Q000191:economics; D006801:Humans; D007356:Insurance, Pharmaceutical Services / Q000331:legislation & jurisprudence*; D038622:Internationality